Literature DB >> 19950178

An active CD8alpha/pMHCI interaction is required for CD8 single positive thymocyte differentiation.

Yoon-Joong Kang1, Xiaosong Wang, Sue-Jane Lin, Yen-Ming Hsu, Hsiu-Ching Chang.   

Abstract

Recognition of viral antigenic peptides bound to major histocompatibility complex class I molecules (MHCI) by TCR is critical for initiating the responses of CD8(+) T cells that ultimately lead to elimination of virus-infected cells. This antigen recognition is enhanced by the CD8 coreceptor through its interaction with the peptide-MHCI complexes (pMHCI). Mouse CD8alphabeta can form two different complexes with pMHCI via either the CD8alpha- or CD8beta-dominated interaction. To understand the functional significance of these complexes in vivo, we generated Tg mice carrying a variant CD8alphabeta (CD8alpha(m3)beta) capable of forming only the CD8beta-dominated CD8alphabeta/pMHCI complex. These mice show sub-optimal thymic differentiation with reduced populations of CD8(+) single-positive thymocytes. Tg CD8(+) T cells exhibit a compromised developmental capacity when competing with CD8(+) T cells from B6 mice in mixed bone marrow chimera experiments. However, once these CD8(+) T cells have emigrated to the peripheral lymphoid organs, they exhibit normal effector function against viral infection. Our observations indicate that, in addition to the CD8 activity conferred by CD8beta-dominated CD8alphabeta/pMHCI complexes, full thymocyte differentiation requires additional coreceptor activities conferred by CD8alphaalpha and/or CD8alphabeta with CD8alpha-dominated CD8/pMHCI complexes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19950178     DOI: 10.1002/eji.200939663

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  1 in total

1.  Specifically differentiated T cell subset promotes tumor immunity over fatal immunity.

Authors:  Abdulraouf Ramadan; Brad Griesenauer; Djamilatou Adom; Reuben Kapur; Helmut Hanenberg; Chen Liu; Mark H Kaplan; Sophie Paczesny
Journal:  J Exp Med       Date:  2017-10-16       Impact factor: 14.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.